Medical Psilocybin

Psychedelic Science and Medicine News Roundup: March 1-12

With each passing week, we are seeing more and more advances in psychedelic research in the scientific and medical fields. Truffle Report has compiled a roundup of major medical and scientific news from the first two weeks of March 2021, making it easier for you to track these ongoing developments.

Innovators Identify Crucial Advancements to Uncover Medical Breakthroughs From Psychedelics

March 2, 2021 – Mind Medicine, Numinus Wellness, Field Trip Health, and Cybin Inc. have all announced clinical research trials that are either planned or are already underway for medicinal psychedelics. MINDCURE also got involved in clinical psychedelic research by partnering with ATMA Journey Centers Inc.

Positive Effects of Psychedelic Microdosing Likely Due to Placebo Effect, Study Finds

March 3, 2021 – A study published in eLife details the results of the largest placebo-controlled trial evaluating the effects of psychedelics to date. The researchers concluded that the psychological benefits of microdoses of psychedelics could be due to the placebo effect and not the substances themselves.

Psychedelic Science Holds Promise for Mainstream Medicine

March 10, 2021 – A team of neuroscientists from the University of Nevada in Las Vegas is studying how psychedelics affect brain activity. Recent research in rodents shows a strong connection between brain activity and behaviours resulting from psychedelic treatment. This could be a step forward in the quest to better understand psychedelics’ potential therapeutic effects and uses. 

See Also
Psychedelic Research Into Lesser Known Indications Image

Microdose Announces the Launch of Accredited Course Series “The Science of Psychedelics: Training for Medical Professionals”

March 10, 2021 – Microdose announced “The Science of Psychedelics: Training for Medical Professionals”, which is an online, accredited course series for physicians, psychologists, social workers, mental health counselors, pharmacists, and other medical professionals. The course has been approved for 8.0 AMA PRA Category 1 Credits™ through the joint providership of CME Consultants and MD Media Inc., as well as accreditation through the American Psychological Association (APA), the California Board of Registered Nursing, the California Board of Behavioral Sciences, and the Oregon Board of Naturopathic Medicine (OBNM).

What makes peyote unique among psychedelics?

Lophos Pharma is a #peyote focused psychedelics company co-founded by wife and husband duo Claire and Evan Stawnyczy to explore mescaline’s therapeutic potential.

Read the full interview here: http://ow.ly/kN6w50I3vzt

The push for medical #DMT is on. Truffle Report looks at top corporate and scientific developments involving the spirit molecule from @mindmedco, @AlgernonPharma, @entheonbiomed, @SmallPharma and more.

Full article here: http://ow.ly/khee50HXOHz

#science #business #medicine

Our CEO and Co-Founder @flobrand spoke to @amanda_siebert @Forbes to give deeper context on the significance of our donation to @MAPS and the importance of collaboration between for-profit and non-profits in tackling the #mentalhealth crisis.

See: https://www.forbes.com/sites/amandasiebert/2022/02/16/exclusive-maps-accepts-500k-donation-from-atai-life-sciences-philanthropy-arm/

A Hawaii legislative committee has approved a bill that proposes the establishment of a working group to study the therapeutic benefits of #psilocybin by a vote of 5-0.

Read the full story here: http://ow.ly/4WWI50HWJtL

#psychedelics #healing #medicine #hawaii #legal

"Inspired by a device created by in the 1950s, the creators hope to bring free transcendental experiences to 100,000 Britons – and unite the country through communal hallucinations"

https://www.theguardian.com/artanddesign/2022/feb/16/dreamachine-unboxed-brion-gysin-jon-hopkins-assemble

Load More...

Related Articles

Scroll To Top